Novo Nordisk: drug efficient for type 2 diabetes in Japan

(CercleFinance.com) - A late stage trial of Novo Nordisk's oral semaglutide found that the experimental drug reduced levels of blood glucose level (HbA1c) and body weight in Japanese people with type 2 diabetes.


The phase 3a trial achieved its primary endpoint, by demonstrating a comparable number of adverse events with oral semaglutide compared to Lilly's dulaglutide, the Danish drugmaker said.

The proportion of people treated with 3, 7 and 14 mg oral semaglutide who experienced gastro-intestinal adverse events were 31%, 39% and 54%, respectively, compared to 40% with dulaglutide, it added.

Copyright (c) 2018 CercleFinance.com. All rights reserved.